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Chronic kidney disease (CKD) is an important public health concern in developed countries because of
both the number of people affected and the high cost of care when prevention strategies are not effectively
implemented. Prevention should start at the governance level with the institution of multisectoral polices
supporting sustainable development goals and ensuring safe and healthy environments. Primordial pre-
vention of CKD can be achieved through implementation of measures to ensure healthy fetal (kidney)
development. Public health strategies to prevent diabetes, hypertension, and obesity as risk factors for
CKD are important. These approaches are cost-effective and reduce the overall noncommunicable disease
burden. Strategies to prevent nontraditional CKD risk factors, including nephrotoxin exposure, kidney
stones, infections, environmental exposures, and acute kidney injury (AKI), need to be tailored to local
needs and epidemiology. Early diagnosis and treatment of CKD risk factors such as diabetes, obesity, and
hypertension are key for primary prevention of CKD. CKD tends to occur more frequently and to progress
more rapidly among indigenous, minority, and socioeconomically disadvantaged populations. Special
attention is required to meet the CKD prevention needs of these populations. Effective secondary pre-
vention of CKD relies on screening of individuals at risk to detect and treat CKD early, using established
and emerging strategies. Within high-income countries, barriers to accessing effective CKD therapies must
be recognized, and public health strategies must be developed to overcome these obstacles, including
training and support at the primary care level to identify individuals at risk of CKD, and appropriately
implement clinical practice guidelines.
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I n recent decades, remarkable progress has been madethat has deepened our understanding of the burden
and consequences of chronic kidney disease (CKD)
around the globe.1–3 Since its formal deﬁnition in 2002
and subsequent classiﬁcation by the US National Kid-
ney Foundation, the term CKD has been widely adop-
ted in clinical practice and policy.3 In 2016, CKD was
the ninth-leading cause of death in high-income
countries.4 Although death rates due to ischemic
heart disease, stroke, and lower respiratory infections
are anticipated to decrease, years of life lost (YLLs) due
to CKD are forecasted to more than double globally by
2040.5 These facts are alarming when one considers
demographic trends of aging and lifestyle patterns in
developed nations, which are associated with increased
CKD risk.6 Large-scale public health investments must
therefore be made across the health system to support
CKD prevention and management.
The prevalence of CKD in high-income countries has
been reported to be around 8.6% in males and 9.6% in
females over age 20 years.7 Those with CKD have a
reduced life expectancy compared with that of the
general population, beginning at an estimated glomer-
ular ﬁltration rate (eGFR) of <60 ml/min per 1.73 m2, in
large part due to the associated increased risk of car-
diovascular disease (CVD).8 CKD and its comorbidities
are also important drivers of health care costs.9 Tradi-
tional and nontraditional risk factors for CKD span a
broad range; they include developmental, physical,
social, cultural, structural, environmental, and genetic
factors.2 It is likely that an substantial proportion of
CKD can be prevented at various levels through pri-
mordial (early, upstream), primary, and secondary in-
terventions.10 Effective interventions to prevent and
delay progression of CKD are well recognized, but
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many barriers exist that limit their widespread imple-
mentation, including cost, gender, age, race, and so-
cioeconomic status, even in high-income settings.11,12
Diabetes, hypertension, and obesity are important
contributors to the global burden of disease and are the
most common traditional risk factors for CKD.13 Nontra-
ditional CKD risk factors include developmental and
gestational factors; kidney stones; exposure to nephro-
toxic medications, climate change, and air pollution; in-
fections; and AKI.2,14 The burden of CKD attributable to
these risk factors is likely considerable, given that many
coexist with the more traditional risk factors.15–21
A comprehensive approach to CKD prevention begins
with understanding the breadth of CKD risk factors,
their frequency and distribution, identifying pop-
ulations at risk, and subsequently implementing miti-
gation strategies. Screening for kidney disease has been
shown to be cost-effective in high-income countries.22 It
is imperative that such activities include vulnerable and
disenfranchised populations within these settings. This
article discusses major strategies to tackle traditional and
nontraditional CKD risk factors and implement CKD
prevention in high-income countries, where health
system barriers should be surmountable.
Primordial Prevention of CKD
Population-based studies from high-income countries
have demonstrated an association between low birth
weight (birth weight < 2.5 kg), being born small for
gestational age (birth weight < 10th percentile for
gestational age), and preterm birth (birth before 37
weeks of gestation) and subsequent risk of CKD or end-
stage kidney disease (ESKD).18,20,23 These associations
are stronger in children and adolescents but continue
up to an advanced age.20,24,25 The link between
developmental circumstances and risk of CKD appears,
at least in part, to be mediated by altered renal devel-
opment in utero or shortly after birth, which is asso-
ciated with a reduced nephron number, subsequent
hyperﬁltration, and predisposition to hypertension.26
Globally, approximately 10% of babies are born pre-
term, a proportion that is similar across income re-
gions,27 with the risk factors in developed countries
including preeclampsia, prior preterm birth, advanced
maternal age, chronic maternal illness, assisted repro-
duction, and multiple gestations.28 The incidence of
low birth weight in high-income countries has been
stable at 7% for >20 years, and is most commonly
associated with preterm birth.29 Both preterm birth and
low birth weight occur more frequently among socio-
economically disadvantaged populations and indige-
nous communities within high-income countries,
where structural, environmental, social, and physical
factors impact fetal and maternal health throughout
gestation and early childhood.30 Additional develop-
mental exposures include preeclampsia,31 which is
associated with higher blood pressure in childhood,
and maternal overweight/obesity and/or diabetes,
which are associated with increased odds of pediatric
kidney disease, dysplasia, and later-life diabetic ne-
phropathy.32,33 In high-income countries, gestational
hypertension/preeclampsia occurs in around 3% of
pregnancies,34 diabetes in around 16% of pregnan-
cies,35 and obesity (body mass index > 30 kg/m2) in
5%–30% of pregnant women.36 These rates are also
generally higher among indigenous, minority, and
disadvantaged populations in these countries. Mothers
who experience preeclampsia or gestational diabetes
are themselves at increased risk of future kidney dis-
ease and diabetes. Developmental programming of CKD
risk is relevant in high-income settings, and especially
so among indigenous, African American, and lower
socioeconomic–level populations who have an estab-
lished increased risk of CKD.14
Primordial prevention of CKD therefore includes
optimization of maternal health prior to and during
pregnancy and ensuring healthy growth and adherence
to healthy lifestyles for children born with low birth
weight, small for gestational age, or preterm (Figure 137).
Healthy mothers begin with healthy girls who receive
good nutrition as children, grow up in safe environ-
ments with adequate resources permitting healthy and
productive lives, are educated, and live in equitable
societies. Such circumstances are fostered by the United
Nations Sustainable Development Goals, requiring
health in all policies, and multisectoral action.38
Public Health Approaches to CKD Prevention
For maximal effectiveness and efﬁciency, strategies to
reduce CKD risk should be integrated into a broad
approach to noncommunicable disease prevention,
especially given the high frequency of comorbidities
with CKD (Figure 2).39 Strategies to tackle lifestyle-
related noncommunicable disease risk factors are most
effective when they are implemented at both the pa-
tient and community levels, are supported by regula-
tion and legislation, and incorporate a multi-component
approach.40–42 Successful public health approaches
include introduction of economic incentives to reduce
prices of healthy food and beverages and increase
taxation on unhealthy products, restriction of food
advertising, regulation of food composition (salt, trans
fats, sugar), support for education and physical activity
programs in schools, provision of public recreation
facilities, and campaigns to limit advertising and sales
of harmful products.43,44 Policies aimed at reducing air
pollution are also required.13,44 The World Health Or-
ganization, endorsed by member states, has developed
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multiple packages to guide countries in developing and
implementing such strategies.45,46 Implementation of
population-level approaches to prevent CKD requires
engagement, action, and commitment across multiple
sectors of government and society.40
Primary Prevention of CKD in Developed
Countries
Mitigation of Major Traditional Risk Factors for CKD
The burden of CKD has risen since 1990 in high-income
settings, and despite generally good access to primary
health care in most developed countries, attributable to
ongoing exposure to risk factors, population aging, and
population growth.13,47 Within developed countries,
the burden of CKD is variable as is the distribution of
predisposing risk factors, which tend to be more prev-
alent in more socioeconomically disadvantaged pop-
ulations.47,48 Risk factor distribution may also differ
betweenmen andwomen and tends to increase with age;
therefore, local epidemiology is relevant in development
of strategies to address local risk factor burdens.49,50 In
many regions, metabolic risk factors are the major
drivers of CKD risk,47,50 and indeed, diabetes remains
the most common cause of CKD globally.13 The contri-
bution of hypertension to the burden of CKD in devel-
oped countries is more variable but remains
signiﬁcant.13 The contribution of environmental and
other nontraditional causes of CKD, including air
pollution, smoking, kidney stones, infections, AKI, and
other factors are increasingly being recognized.15,51 A
holistic approach to disease prevention, as highlighted
by the United Nations Sustainable Development Goals,
is therefore likely to have a positive impact on the CKD
burden from diverse causes (Figure 1).38
In 2019, in high-income countries, 10.4% of people
aged 20–79 years are living with diabetes, which
translates into 95.2million individuals, 38.2%whom are
undiagnosed.35 A further 11.4% of the population have
impaired glucose tolerance and are therefore at risk of
diabetes.35 Data from country surveys in 12 high-income
countries reported prevalence rates of hypertension
(deﬁned as blood pressure >140/90 mm Hg) ranging
from 33% to 59% in women and 34% to 59% in men
aged 40–79 years.52 Overall, across the 12 countries,
awareness of hypertension ranged from 56% to 84%,
treatment from 39% to 81%, and control from 17% to
69%.52 In 2014, rates of overweight (body mass index>
25) in adults over 18 years in high-income countries
were 61.5% in men and 52.2% in women.53 In 2018,
7.2% of children in high-income countries were over-
weight, amounting to 5 million children, a 21% increase
since 2000.54 Obesity is a major contributor to
hypertension and diabetes.53,55 Thus, diabetes, hyper-
tension, and overweight/obesity occur commonly in
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high-income countries, and despite access to primary
care in most settings, a signiﬁcant number of people will
remain undiagnosed and/or undertreated, and therefore
at increased risk of developing CKD.
The prevalence of CKD in adults with type 2 diabetes
(T2D) ranges from 25% to 40%, depending on the
population studied.56–58 In a United States population-
based study, CKD (deﬁned as an eGFR of 15–59 ml/min
or microalbuminuria) was present in 40% and 42% of
subjects with diagnosed and undiagnosed diabetes,
respectively.59 CKD occurred in 17.7% of those with
prediabetes and 10.6% without diabetes.59 Similarly,
28% of subjects with diagnosed hypertension were
found to have CKD.60 CKD was present in 17%, 22%,
and 13% of subjects with prehypertension, undiag-
nosed hypertension, or normal blood pressure, respec-
tively.60 The prevalence of CKD among obese subjects
in this population was 17%.58 A concerning ﬁnding
is that the majority of individuals with CKD in devel-
oped countries are unaware of their diagnosis.61–65
Systematic screening for diabetes, hypertension, and
obesity can identify individuals at risk of CKD and
permit early diagnosis and intervention to prevent CKD
and other comorbidities related to these conditions
(Table 1).61,66–68
A graded risk for CKD exists with diabetes and hy-
pertension, implying some causality and therefore
potential for prevention of CKD through reduction in the
burdens of hypertension and diabetes. It is clear that
reduction of structural and lifestyle-related risks is key to
reduce the burdens of diabetes, hypertension, and
obesity, and that many population-level interventions are
cost-effective over the long term.69,70 Similarly, optimi-
zation of upstream factors, including poverty, unhealthy
diets, food insecurity, tobacco consumption, and seden-
tary lifestyle will address other factors impacting CKD
risk and contribute to CKD prevention.71–74 Interventions
to manage hypertension and promote weight loss indeed
have been associated with reduced risk of CKD as well as
improved outcomes in those with CKD.67,75–81
Mitigation of Nontraditional Risk Factors for CKD
Not all CKD results from diabetes, hypertension, and
obesity; therefore, awareness of additional nontradi-
tional risk factors is key to successful prevention of CKD
(Figure 1).48 AKI is being recognized increasingly as an
important risk factor for CKD in both adults and chil-
dren.2,82 In high-income countries, the majority of AKI
occurs in hospital, with an incidence rate of 10%–
20%.83,84 Major risk factors for AKI include pre-existing
CKD, extremes of age, exposure to nephrotoxic sub-
stances, renal hypoperfusion, and infection.85 These risk
factors in hospitalized patients are often superimposed
on existing comorbidities that increase the risk of CKD,
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Figure 2. Highlighting the importance of public health strategies and advocacy for the prevention of chronic kidney disease. AKI, acute kidney
injury. Images reproduced with permission from World Kidney Day. Copyright ªWorld Kidney Day 2006–2020.
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such as diabetes, hypertension, and obesity. Incomplete
recovery of AKI, and thereby progression to acute kid-
ney disease and CKD occurs in approximately 10% of
those experiencing AKI in high-income countries.84
There is still no established targeted treatment for AKI
beyond minimization of further kidney injury, so pre-
vention is key. Multiple strategies have been suggested
for prevention of AKI, including campaigns to increase
awareness of AKI, introduction of electronic alert sys-
tems,86,87 development of prediction algorithms,88 and
clinical pathways across the spectrum of health care,
although the long-term impact of such measures re-
quires further study.85 Documentation of AKI episodes
in discharge summaries and follow-up after AKI is
important for detecting CKD early.86,89
Nephrotoxic agents such as nonsteroidal anti-
inﬂammatory drugs (NSAIDS), antibiotics, iodinated
contrast media, and chemotherapeutic drugs are
frequent causes of AKI, and the association is often fairly
clear given the short lag-times between administration
of the dose and the change in kidney function.87,90 The
contribution of nephrotoxic agents to CKD, such as
proton-pump inhibitors, is more challenging to deﬁne as
the onset is more insidious.16 The pathophysiology of
chronic nephrotoxicity ranges from interstitial inﬂam-
mation to tubular and glomerular injury.16,91,92 Also
important is that the use of alternative remedies is
frequent in high-income settings and may play an
under-recognized role in the development of both AKI
and CKD.93–95 Both the public and health care practi-
tioners must be aware of the risks of nephrotoxicity
from medication and alternative remedies, as well as of
potential interactions between the two, so that use can
be minimized or optimized as a strategy to prevent CKD.
Calls for better regulation of alternative remedies are
required to improve standardization of products and
develop appropriate understanding and warning
regarding potential toxicities.10
Kidney stones are common in high-income countries,
with prevalence rates of 7%– 13% in North America,
5%–9% in Europe, and 20% in Saudi Arabia.96,97
People with kidney stones are at increased risk of
developing CKD, in part because of shared risk factors,
such as diabetes, hypertension, obesity, metabolic
syndrome, and CVD, as well as direct kidney injury
from obstruction or crystal precipitation.98,99 Certain
forms of bariatric surgery are emerging as an important
cause of kidney stones in developed countries.100
Occupational risks and climate change also increase
stone risk.96,97,101 The risk of a stone event increases
after the ﬁrst event; therefore, prevention of recurrent
stones is important to reduce the risk of CKD.98,102
Dietary changes, including increasing ﬂuid intake,
avoiding sweetened beverages, reducing dietary so-
dium and red meat intake, and ensuring sufﬁcient di-
etary calcium have all been shown to reduce stone
risk.96,102 Population-level strategies to reduce the risk
of hypertension, diabetes, metabolic syndrome, and
obesity are also likely to reduce stone risk and thereby
prevent CKD. Advocacy is required to educate the
public and to ensure that occupation and climate risks
are mitigated as effectively as possible.
Table 1. Population-level compliance with strategies for primary and secondary prevention of CKD
Risk factor
Evidence-based recommendation: guideline-concordant
treatment goals and recommended agents Population-level compliance
Awareness Low compliance: 90% of individuals with 2–4 CKD markers
and 84% of individuals with$5 CKD markers were unaware
of their disease61
Lifestyle
Overweight BMI < 25 kg/m2
Diet Low salt (<2 g/d)
Smoking Smoking cessation
Exercise 30–60 min of exercise 4–7 d/wk
Proteinuria/albuminuria Monitoring and follow-up
Treatment with ACEi/ARBs, with proteinuria >30 mg/mmol or 0.5 g/d
20% detection rate for CKD-related albuminuria at the
community level
Prevalence of ACEi/ARB use decreased from 45% in 2006–
2008 to 36% in 2012–201466
Blood pressure <130/80 mmHg (diabetes or proteinuric CKD)a
<140/80 mm Hg (nondiabetic or nonproteinuric CKD)
Prevalence of uncontrolled hypertension (>130/80 mm Hg)
was 46%–48% over the past decade66
Diabetes HbA1c <7% and use of newer agents (i.e., SGLT2 may have role in CKD
stages 1–4 for signiﬁcant cardiovascular and kidney outcomes beneﬁts)
Prevalence of uncontrolled diabetes (HbA1c >7%) was
w40% in 2012–201466
Dyslipidemia Use of statinsb Statin use among patients with CKD aged $50 years was
low and remained basically unchanged, increasing slightly
from 29% in 2006–2008 to 31% in 2012–201466
Cardiovascular Use of aspirin, beta-blockers among patients with established CVD
BMI, body mass index; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin-receptor blocker; CKD, chronic kidney disease; CVD, cardiovascular disease; HbA1c, glycated
hemoglobin; SGLT2, sodium-glucose cotransporter-2.
aUse of ACEi/ARBs recommended.
bFire and forget strategy (use of statins among all CKD patients aged >50 years, and no need for serial lipid panels monitoring).
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Preeclampsia is being recognized increasingly as a
risk factor for CKD. In a Danish population cohort, the
risk of CKD in women who had experienced pre-
eclampsia was at least double that seen in women
without a history of preeclampsia.103 In a Canadian
population-based study, a woman having been born
preterm herself was associated with an increased risk
of preeclampsia.104 CKD itself increases the risk of
preeclampsia, and therefore a subtle programmed
decrease in kidney function prior to pregnancy in
mothers born preterm may confound this relationship.
Women who had been born preterm also had a higher
risk of delivering preterm.104 Where the cycle begins
is therefore unclear, but preterm birth is both a result
of and a risk factor for future CKD, in both the mother
and the offspring, and is a risk factor for preeclampsia
itself, which is in turn a risk factor for preterm birth
and CKD in the mother and the offspring. Both pre-
term birth and preeclampsia are common, so screening
and follow-up of kidney function in individuals who
experience these events is important to reduce the
CKD burden.18,103 Awareness must be raised among
health care professionals such that women and infants
at risk can be identiﬁed in the delivery room. Edu-
cation and encouragement regarding adherence to
healthy lifestyles, as well as lifelong access to primary
care are key to mitigating long-term risk for both.
Many structural risk factors likely contribute to both
preterm birth and CKD, including poverty, lack of
access to antenatal care, poor maternal nutrition, ex-
tremes of maternal age, maternal illness, and gender
inequality.30 Hypertension, diabetes, CVD, and
obesity are all also risks factors for and consequences
of preeclampsia and preterm birth that highlight the
importance of a life-course approach to CKD preven-
tion (Figure 1).30
The use of illicit substances such as cocaine, heroin,
or methamphetamine has also been linked with an
increased risk for CKD progression and increased
mortality risk among adults with established
CKD.105,106 Infections such as endocarditis, hepatitis B
and C, and HIV also increase the risk factors for CKD.10
Furthermore, heavy metal pollutants (e.g., arsenic,
cadmium, lead, and mercury) and other environmental
toxins have been shown to be harmful to the kidneys.
Exposure to particulate matter (small particles
including dust and dirtw2.5–10 mm or smaller) also is
associated with the risk of developing de novo CKD at
the general population level.15,107 Public health stra-
tegies that target these nontraditional factors while
promoting better control of traditional factors, such as
hypertension, CVD, and diabetes, may signiﬁcantly
impact the future population-based burden of CKD in
industrialized nations.10
Secondary Prevention of CKD in the Developed
World
Considering the public health burden of CKD and the
availability of evidence-based treatment for its man-
agement, health systems in developed countries must
implement prevention strategies to reduce population
impacts of the disease. Secondary prevention in the
form of early detection of CKD could promote the use of
effective interventions to reduce the risks of adverse
outcomes associated with the disease, such as CVD
events, ESKD, and increased mortality risk.108
CKD Early Detection and Prevention Programs
Early detection, appropriate risk stratiﬁcation, and
subsequent treatment of CKD may delay or prevent
many associated complications and decrease overall
health care costs.109,110 Screening the general popula-
tion for early CKD is not cost-effective, and therefore is
unwarranted.6 Selective screening should be directed
toward high-risk groups, speciﬁcally older persons and
those with hypertension and diabetes, as well as some
ethnic groups such as African Americans, and indige-
nous populations of Canada, the United States, and
Australia.109,111,112 Targeted screening of high-risk in-
dividuals, such as those with diabetes or hypertension
or both, is cost-effective.113,114 For instance, the cost-
effectiveness of a screening program for proteinuria
among US adults with hypertension and diabetes has
been clearly demonstrated; angiotensin-converting
enzyme inhibitor/angiotensin-receptor blockers have
been shown to reduce mortality and slow the pro-
gression of kidney disease among at-risk individuals
identiﬁed through this screening program.114 The
guidelines therefore recommend screening only at-risk
individuals for CKD (Table 2).115–127
An international survey of kidney care evaluated the
practice patterns for routine CKD testing among several
high-risk populations.128 Across countries in all income
groups, CKD testing was found to be almost universally
available for patients with hypertension and diabetes
(94%–100%), but minimal for high-risk ethnic pop-
ulations (<30%).129 More than 50% of countries tested
patients with CVD who were taking chronic nephro-
toxic medications and had a family history of CKD.
Elderly populations (age$65 years) also were tested for
CKD in more than half of the countries in the high-
income and upper-middle–income groups, but in less
than half of the countries in the lower-middle–income
(47%) and low-income (41%) groups. Overall, CKD
testing rates followed the economic development clas-
siﬁcation pattern, with the highest rates in higher-
income countries and the lowest rates in low-income
countries. Individual studies report variable screening
for CKD, although interventions to improve adherence
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Table 2. Screening recommendations by the professional medical and nephrology societies
Organization
Nature of
organization Date Population
Recommendation
statement
Strength and evidence of
recommendation
US Preventive
Services Task
Force117
Government/
generalist
2012 Asymptomatic adults without
diagnosed CKD
No recommendation Grade: I (insufﬁcient Evidence): The evidence is
insufﬁcient to assess the balance of beneﬁts and
harms of routine screening for CKD in
asymptomatic adults. Evidence is lacking, of poor
quality, or conﬂicting, and the balance of beneﬁts
and harms cannot be determined.
ACP118 Generalist 2013 Asymptomatic adults without
risk factors for CKD
ACP recommends against screening for
CKD in asymptomatic adults without risk
factors for CKD.
Grade: weak recommendation, low-quality
evidence
American
Academy of
Family
Physicians119
Generalist 2014 Endorsed recommendation made by
the ACP
NICE, UK120 Generalist 2014;
updated
2015
People prescribed
nephrotoxic drugs
1.1.27 Monitor eGFR at least annually for
people prescribed drugs known to be
nephrotoxic, such as calcineurin inhibitors
(for example, cyclosporin or tacrolimus),
lithium, and nonsteroidal anti-inﬂammatory
drugs (NSAIDs). [2008, amended 2014]
Strong
People with risk
factors for CKD
1.1.28 Offer testing for CKD using eGFR
creatinine and ACR to people with any of the
following risk factors: diabetes,
hypertension, acute kidney injury,
cardiovascular disease (ischemic heart
disease, chronic heart failure, peripheral
vascular disease, or cerebral vascular
disease), structural renal tract disease,
recurrent renal calculi or prostatic
hypertrophy, and multisystem diseases with
potential kidney involvement, e.g., systemic
lupus erythematosus, family history of end-
stage kidney disease (GFR category G5) or
hereditary kidney disease, opportunistic
detection of hematuria.
Strong
Asymptomatic adults 1.1.29 Do not use age, gender, or ethnicity
as risk markers to test people for CKD. In the
absence of metabolic syndrome, diabetes or
hypertension, do not use obesity alone as a
risk marker to test people for CKD. [2008,
amended 2014]
Strong
American Society
of Nephrology121
Renal
organization
2013 Asymptomatic adults Strongly recommends regular screening for
kidney disease, regardless of an individual’s
risk factors
National Kidney
Foundation/
Kidney Disease
Outcomes
Quality Initiative122,123
Renal
organization
2002 Individuals at risk for CKD Guideline 3: individuals at increased risk of
CKD: Some individuals without kidney
damage and with normal or elevated GFR
are at increased risk for development of CKD.
All individuals should be assessed, as part
of routine health encounters, to determine
whether they are at increased risk of
developing CKD, based on clinical and
sociodemographic factors.
Individuals at increased risk of developing
CKD should undergo testing for markers of
kidney damage and to estimate the level of
GFR. Individuals found to have CKD should
be evaluated and treated as speciﬁed in
Guideline 2. Individuals at increased risk but
found not to have CKD should be advised to
follow a program of risk factor reduction, if
appropriate, and undergo
repeat periodic evaluation.
Opinion
2013 Individuals at risk for CKD The commentary work group endorses the
recommendations from the original guideline
for screening among individuals at high risk
for CKD despite the absence of this speciﬁc
recommendation in the KDIGO guideline,
and as such is in agreement with the
recommendation of the ACP to screen
asymptomatic adults only if they are at high
risk for CKD.
Opinion
(Continued on next page)
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to guidelines have proved beneﬁcial.130 Follow-up of
kidney function after an initial abnormal value and
screening for albuminuria is suboptimal even in coun-
tries with universal health coverage, and tends to be
lower among populations with lower socioeconomic
status.131,132 Education of ﬁrst-line health care workers
and primary care physicians is important to improve
appropriate screening for early detection and treatment
of CKD.130,133 Strengthening of primary care capacity is
required, including support from concise guidelines and
management protocols, electronic medical records with
in-built decision support systems, multidisciplinary
teams, and novel knowledge translation tools.
Current State of Secondary Prevention
Effective strategies are available to slow the progres-
sion of CKD to ESKD and reduce the risk of cardio-
vascular events and mortality (Table 1). Lifestyle
behavior changes are necessary and have been associ-
ated variably with improvements in body mass index,
blood pressure, diet, exercise, and renal function in
patients with CKD.134 Clinical strategies to manage CKD
include dietary manipulations of protein intake, inhi-
bition of the renin–angiotensin–aldosterone system,
and strategies to control glycemia and dyslipidemia.135
Among these interventions aimed at slowing CKD
progression and mitigating CVD outcomes, inhibition
of the renin–angiotensin–aldosterone system has yiel-
ded the most impact, is cost-effective in high-income
settings, and has been adopted as an integral part of
CKD management practices worldwide.6,136
Given that T2D is the major driver of CKD, pre-
vention of CKD in people with diabetes could have a
major impact on the global CKD burden. Despite good
evidence of their impact, uptake of renin–angiotensin–
aldosterone system inhibitors early on was surprisingly
slow.115,137 Medications that inhibit the sodium-
glucose cotransporter-2 (SGLT2) and glucagon-like
peptide-1 receptor agonists (GLP1RAs) are emerging
as important additional therapies for secondary
Table 2. (Continued) Screening recommendations by the professional medical and nephrology societies
Organization
Nature of
organization Date Population
Recommendation
statement
Strength and evidence of
recommendation
KDIGO124 Renal
organization
2013 Screening of CKD was beyond the scope of
the CKD work group and no speciﬁc
recommendations were made.
Canadian Society
of Nephrology125
Renal
organization
2015 Asymptomatic individuals No screening Consensus
At risk of CKD Practitioners should continue to use case
ﬁndings in keeping with usual clinical
practice: in people with new-onset or long-
standing hypertension or diabetes, people
with vascular disease, people who are to
undergo major surgery or be exposed to
other potential causes of acute kidney injury,
people with multisystem or generalized
symptoms, people who are being considered
for nephrotoxic medications or medications
that require dose adjustment for renal
function, people with a family history of
polycystic kidney disease or hereditary
nephritis, and people from First Nations
populations or other ethnic groups known to
be at increased risk.
Consensus
KHA-CARI
Guidelines126
Renal
organization
2013 Diabetes, hypertension, or
established CVD
We recommend that screening for CKD be
targeted and performed in individuals at
increased risk of developing CKD, including
those with diabetes mellitus, hypertension,
and established CVD.
1B
Additional risk factors such as obesity,
cigarette smoking; Aboriginal and
Torres Strait Islander peoples;
family history of stage 5 CKD
or hereditary kidney disease in a
ﬁrst- or second-degree relative;
and severe socioeconomic
disadvantage
We recommend screening in those with
additional CKD risk factors identiﬁed in
guideline 2a (obesity, cigarette smoking,
Aboriginal and Torres Strait Islander peoples,
family history of stage 5 CKD or hereditary
kidney disease in a ﬁrst- or second-degree
relative and severe socioeconomic
disadvantage) (1D)
1D
UK Renal
Association127
Renal
organization
2011 At risk for CKD Guideline 1.4—CKD: detection and
monitoring of CKD: We recommend that
patients who are at increased risk for
developing CKD should be offered screening
tests to detect CKD.
1B
ACP, American College of Physicians; ACR, albumin-to-creatinine ratio; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular ﬁltration rate; KDIGO:
Kidney Disease: Improving Global Outcomes; KHA-CARI: Kidney Health Australia—Caring for Australasians with Renal Impairment; NICE: National Institute of Health and Care
Excellence; UK, United Kingdom; US, United States.
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prevention of diabetic nephropathy; more awareness is
required to optimize uptake. SGLT2 inhibitors were
originally developed as glucose-lowering therapies, but
they also have multiple other physiological effects,
including natriuresis, suppression of pro-inﬂammatory
and pro-ﬁbrotic factors, and reduction in tissue
ischemia in the heart and kidney.138–140 In recent
published cardiovascular outcome trials, the SGLT2
inhibitors signiﬁcantly reduced the risk of cardiorenal
endpoints in patients with T2D. For example, in pa-
tients with established atherosclerotic CVD, empagli-
ﬂozin signiﬁcantly reduced 3-point major adverse
cardiac events, cardiovascular and overall mortality,
hospitalization for heart failure, and the composite
renal secondary endpoint (EMPA-REG
OUTCOME).141,142 Subsequently, in a cohort with
lower overall cardiovascular risk, canagliﬂozin also
reduced 3-point major adverse cardiac events, hospi-
talization for heart failure, and renal endpoints, but it
did not impact mortality (CANVAS Program).143 In a
third trial,144 dapagliﬂozin reduce the co-primary
endpoint (cardiovascular death or hospitalization for
heart failure), and also reduced renal risk, even though
only 40% of participants had established atheroscle-
rotic CVD at baseline, with a mean eGFR of 85 ml/min
per 1.73 m2. In a trial with dedicated renal endpoints,
canagliﬂozin treatment in type 2 diabetic nephropathy
(CREDENCE), in addition to renin-angiotensin-
aldosterone system blockade, was associated with a
30% decline in the primary composite endpoint, con-
sisting of doubled serum creatinine level, ESKD, renal
or cardiovascular death; also reported were signiﬁcant
cardiovascular beneﬁts.145 In this study, canagliﬂozin
was continued in patients with GFR < 30 ml/min,
suggesting potential safety beyond this threshold,
although more data are required.
Given the profound protection against hospitalization
for heart failure in the early trials, several dedicated
trials in patients with heart failure are either underway
or have been completed. In the ﬁrst of these studies,
dapagliﬂozin treatment in patients with heart failure and
reduced ejection fraction, with or without T2D at
baseline (DAPA HF), reduced the risk of cardiovascular
death or heart failure endpoints by 24%, regardless of
diabetes status.146 The positive cardiovascular impact of
SGLT2 inhibitors therefore extends to those without
diabetes; however, results of 2 dedicated ongoing trials
are awaited to assess their potential role in secondary
prevention of nondiabetic kidney disease.147
The GLP1RAs are also used primarily as glucose-
lowering therapies and to induce weight loss. In
several cardiovascular outcome trials, GLP1RAs have
been shown to reduce 3-point major adverse cardiac
events and speciﬁc atherosclerotic CVD
endpoints.148,149 From a renal perspective, GLP1RA,
liraglutide (LEADER), and semaglutide (SUSTAIN-6)
reduced composite renal endpoints, consisting of pro-
gression of albuminuria, doubling of serum creatinine
level, renal replacement therapy, or renal death.150 In
contrast to SGLT2 inhibitors, with which the risk of
hard renal endpoints was reduced, renal beneﬁts of
GLP1RA were primarily due to an attenuation of pro-
gression of albuminuria.150 Nevertheless, eGFR decline
over 52 weeks was signiﬁcantly lower with dulaglutide
versus insulin in patients with CKD stages 3–4
(AWARD-7); eGFR was better preserved in subjects
with CKD stage 3 with liraglutide versus placebo
(LEADER); and the risk of losing 40% or 50% of kid-
ney function was signiﬁcantly lower with dulaglutide
versus placebo (REWIND), suggesting some beneﬁt for
secondary prevention of CKD.150–154 Semaglutide is
currently being studied as a renal protective therapy in
patients with renal impairment and albuminuria in the
FLOW trial.
Current evidence is encouraging that these new
medications may have a signiﬁcant impact on reducing
CKD progression and CVD morbidity, but ongoing
vigilance is required. SGLT2 inhibition increases the
risk of genital tract infections, and it has been linked
with a small but signiﬁcant increase in the risk of
diabetic ketoacidosis, even in patients with T2D.144 In
addition, in the CANVAS Program, major and minor
amputation and the risk of fracture were higher in
canagliﬂozin-treated patients versus placebo-treated
patients—risks that have not been reported in any
other trials.145 As a result, clinical concern around
these issues has diminished, especially since patients in
CREDENCE were at high risk for amputation at baseline
given their background of signiﬁcant CKD. However,
good genital/perineal hygiene, awareness of symptoms
of ketoacidosis, and regular foot examination are rec-
ommended during therapy.155 As conﬁdence builds
around the place of these medications in secondary
prevention of CKD, advocacy will be required to ensure
equitable and affordable access globally.
Awareness, Disparities, Capacity, and Barriers
to Effective Prevention
Despite progress, signiﬁcant gaps in care remain at the
policy, health system, and individual levels across the
spectrum of CKD prevention.61,66,132 The International
Society of Nephrology collected data on country-level
capacity for kidney care delivery using a survey
aligned with the World Health Organization’s health
system building blocks, and published the ﬁndings in
the ﬁrst and second edition of the Global Kidney Health
Atlas.128 This document highlighted limited awareness
and prioritization of CKD, as well as persistent
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inequities in resources required to tackle the burden of
kidney disease globally. Overall, CKD was recognized
as a health care priority by just 36% of governments.
Surprisingly, the priority accorded to CKD care was
inversely related to country income level, but less so in
upper-middle– and high-income countries (30%)
compared with low- and lower-middle–income coun-
tries (50%). This pattern is also reﬂected in the funding
and delivery of CKD care across high-income nations.
Government-provided universal health coverage for
kidney disease (CKD and ESKD) is common in devel-
oped nations, but with substantial variability in how
care is funded and delivered. For instance, in the
United States, ESKD care is publicly ﬁnanced for resi-
dents; however, optimal treatment of CKD and its risk
factors is generally not accessible for persons lacking
health insurance.156 Barriers to providing optimal CKD
care, including patient factors (e.g., awareness, treat-
ment compliance), care provider factors (e.g., limited
awareness and/or inertia in the application of optimal
CKD management practices, time and resource con-
straints), and system factors (e.g., prioritization, fund-
ing, availability of functional infrastructures) are
frequently reported. Disparities in the burden of dis-
ease and quality of care are clearly demonstrated for
African Americans in the US, indigenous populations
in Australia and Canada, Indo-Asian communities in
the UK, and multiple other settings in the developed
world.12,74,157,158 Given that the CKD burden tends to
be highest in these communities, implementation of
appropriate and acceptable prevention strategies is an
urgent need.
Despite guidelines regarding management of car-
diovascular and renal risk, surprising gaps still exist in
guideline-concordant care delivery. In a national study
of over 40,000 Canadians with early CKD managed in
primary care, signiﬁcant gaps were found in the use of
urine protein excretion as a screening tool and around
the rate of use of proven medications to reduce car-
diovascular and renal risk associated with protein-
uria.132 Many patients received high-quality care for
other domains (blood pressure and glycemic control),
but awareness about the implications of elevated urine
protein and its impact on health outcomes was identi-
ﬁed as an area for improvement. This is a familiar
picture demonstrated in similar high-income set-
tings.66,159 The proliferation of guideline recommen-
dations targeting primary care, however, constitutes a
barrier in itself to sustainable implementation of
optimal management of chronic diseases including
CKD.66,159–161 For example, an average primary care
physician would require about 7–10 hours per working
day to follow preventive recommendations for the
common chronic diseases.162,163
Conclusion
Prevention of CKD is possible but requires a broad and
holistic approach—ranging from good governance and
achievement of the sustainable development goals, to
ensuring healthy pregnancies for a good start in life—
and access to appropriate screening for early detection
and treatment of risk factors for CKD as well as of early
CKD (Figure 2). The management of traditional risk
factors has improved in certain countries, but signiﬁ-
cant gaps in care remain even in developed countries,
particularly with regard to identifying early risk (e.g.,
detection and monitoring of albuminuria) and
addressing these risks, especially in disadvantaged
sectors of the population. Nontraditional risk factors
remain underappreciated in many settings. Closing
these gaps will require multifaceted stakeholder
engagement, including the development and imple-
mentation of strong public health measures to prevent
CKD risk factors, especially diabetes, hypertension, and
obesity; patient advocacy and awareness tools; and
promotion of self-management programs. Strong pri-
mary care capacity must also be developed to imple-
ment target screening, early diagnosis, and early
treatment strategies, followed by long-term access to
appropriate secondary prevention and care.
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